July 14 (Reuters) - Gilead Sciences Inc GILD.O
* Gilead receives approval in Canada for Epclusa (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic Hepatitis C Source text for Eikon: ID:nCNW0pfbha Further company coverage: GILD.O